Survival in diffuse large B cell lymphoma by International Prognostic Index (IPI)

Event-free survival (EFS), progression-free survival (PFS), and overall survival (OS), according to International Prognostic Index (IPI) score in rituximab-treated patients with diffuse large B cell lymphoma (DLBCL) from the MabThera International Trial (MInT; ≤60 years, age-adjusted IPI [aaIPI] 0, 1; n = 380); MegaCHOEP (dose-escalated regimen of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) trial (≤60 years, aaIPI 1-3; n = 72); RICOVER-60 (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab for patients older than age 60 years) trial (>60 years, all IPI groups; n = 610); and all trials (18 to 80 years of age, all IPI groups; n = 1062).